spacer.gif

Nächstes SAL-Treffen

Herbst 2018

15.-16. November 2018: SAL- Herbst-Studiengruppentreffen & AML-Academy

Dresden

Programm

Online Anmeldung

alle Veranstaltungen
 

Publikationen

2016   
2015   
2014   
2013   
2012   
2011   
2010   
2009   
2008   
2007   
2006   
2005   
2004   
2003   
2002   
2001   
2000   
1999   

2016

Kayser S, Benner A, Thiede C, Martens U, Huber J, Stadtherr P, Janssen JW, Röllig C, Uppenkamp MJ, Bochtler T, Hegenbart U, Ehninger G, Ho AD, Dreger P, Krämer A. Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Blood Cancer J. 2016 Jul 29;6(7):e449. doi: 10.1038/bcj.2016.46. PubMed PMID: 27471865; PubMed Central PMCID: PMC5030374.

Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P,  Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J Clin Oncol. 2016 Jul 11. pii: JCO671982. [Epub ahead of print] PubMed PMID: 27400939.

Kaifie A, Isfort S, Gattermann N, Hollburg W, Klausmann M, Wolf D, Maintz C, Hänel M, Goekkurt E, Göthert JR, Platzbecker U, Geer T, Parmentier S, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S; Study Alliance Leukemia (SAL).. Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians. Ann Hematol. 2016 Sep;95(9):1399-410. doi: 10.1007/s00277-016-2730-y. PubMed PMID: 27334946.

Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N, Gökkurt E, Platzbecker U, Hollburg W, Göthert JR, Parmentier S, Lang F, Hansen R, Isfort S, Schmitt K, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S; Study Alliance Leukemia (SAL).. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol. 2016 Mar 5;9:18. doi: 10.1186/s13045-016-0242-9. PubMed PMID: 26944254; PubMed Central PMCID: PMC4779229.

Stölzel F, Mohr B, Kramer M, Oelschlägel U, Bochtler T, Berdel WE, Kaufmann M, Baldus CD, Schäfer-Eckart K, Stuhlmann R, Einsele H, Krause SW, Serve H, Hänel M, Herbst R, Neubauer A, Sohlbach K, Mayer J, Middeke JM, Platzbecker U, Schaich M, Krämer A, Röllig C, Schetelig J, Bornhäuser M, Ehninger G. Karyotype complexity and prognosis in acute myeloid leukemia. Blood Cancer J. 2016 Jan 15;6:e386. doi: 10.1038/bcj.2015.114. PubMed PMID: 26771812; PubMed Central PMCID: PMC4742631.

Middeke JM, Herold S, Rücker-Braun E, Berdel WE, Stelljes M, Kaufmann M, Schäfer-Eckart K, Baldus CD, Stuhlmann R, Ho AD, Einsele H, Rösler W, Serve H, Hänel M, Sohlbach K, Klesse C, Mohr B, Heidenreich F, Stölzel F, Röllig C, Platzbecker U, Ehninger G, Bornhäuser M, Thiede C, Schetelig J; Study Alliance Leukaemia (SAL).. TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2016 Mar;172(6):914-22. doi: 10.1111/bjh.13912. PubMed PMID: 26771088.

Ho AD, Schetelig J, Bochtler T, Schaich M, Schäfer-Eckart K, Hänel M, Rösler W, Einsele H, Kaufmann M, Serve H, Berdel WE, Stelljes M, Mayer J, Reichle A, Baldus CD, Schmitz N, Kramer M, Röllig C, Bornhäuser M, Thiede C, Ehninger G; Study Alliance Leukemia.. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD. Biol Blood Marrow Transplant. 2016 Mar;22(3):462-9. doi: 10.1016/j.bbmt.2015.10.023. PubMed PMID: 26551637.

Müller-Tidow C, Tschanter P, Röllig C, Thiede C, Koschmieder A, Stelljes M, Koschmieder S, Dugas M, Gerss J, Butterfaß-Bahloul T, Wagner R, Eveslage M, Thiem U, Krause SW, Kaiser U, Kunzmann V, Steffen B, Noppeney R, Herr W, Baldus CD, Schmitz N, Götze K, Reichle A, Kaufmann M, Neubauer A, Schäfer-Eckart K, Hänel M, Peceny R, Frickhofen N, Kiehl M, Giagounidis A, Görner M, Repp R, Link H, Kiani A, Naumann R, Brümmendorf TH, Serve H, Ehninger G, Berdel WE, Krug U; Study Alliance Leukemia Group.. Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia. Leukemia. 2016 Mar;30(3):555-61. doi: 10.1038/leu.2015.306. PubMed PMID: 26522083.

Middeke JM, Herbst R, Parmentier S, Bug G, Hänel M, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, Morgner A, Kramer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehninger G, Bornhäuser M, Schetelig J. Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial. Leukemia. 2016 Feb;30(2):261-7. doi: 10.1038/leu.2015.226. PubMed PMID: 26283567.

Crysandt M, Kramer M, Ehninger G, Bornhäuser M, Berdel WE, Serve H, Röllig C, Kaifie A, Jost E, Brummendorf TH, Wilop S. A high BMI is a risk factor in younger patients with de novo acute myelogenous leukemia. Eur J Haematol. 2016 Jul;97(1):17-24. doi: 10.1111/ejh.12675. PubMed PMID: 26277604.

2015

Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia.. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015 Dec;16(16):1691-9. doi: 10.1016/S1470-2045(15)00362-9. PubMed PMID: 26549589.

Thiel A, Schetelig J, Pönisch W, Schäfer-Eckart K, Aulitzky W, Peter N, Schulze A, Maschmeyer G, Neugebauer S, Herbst R, Hänel A, Morgner A, Kroschinsky F, Bornhäuser M, Lange T, Wilhelm M, Niederwieser D, Ehninger G, Fiedler F, Hänel M; East German Study Group Hematology/Oncology (OSHO).; Study Alliance Leukemia (SAL).. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL). Ann Oncol. 2015 Jul;26(7):1434-40. doi: 10.1093/annonc/mdv205. PubMed PMID: 25922062.

Röllig C, Bornhäuser M, Kramer M, Thiede C, Ho AD, Krämer A, Schäfer-Eckart K, Wandt H, Hänel M, Einsele H, Aulitzky WE, Schmitz N, Berdel WE, Stelljes M, Müller-Tidow C, Krug U, Platzbecker U, Wermke M, Baldus CD, Krause SW, Stölzel F, von Bonin M, Schaich M, Serve H, Schetelig J, Ehninger G. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial. J Clin Oncol. 2015 Feb 10;33(5):403-10. doi: 10.1200/JCO.2013.54.4973. Erratum in: J Clin Oncol. 2015 May 1;33(13):1519. PubMed PMID: 25547501.

Schetelig J, Schaich M, Schäfer-Eckart K, Hänel M, Aulitzky WE, Einsele H, Schmitz N, Rösler W, Stelljes M, Baldus CD, Ho AD, Neubauer A, Serve H, Mayer J, Berdel WE, Mohr B, Oelschlägel U, Parmentier S, Röllig C, Kramer M, Platzbecker U, Illmer T, Thiede C, Bornhäuser M, Ehninger G; Study Alliance Leukemia. Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial. Leukemia. 2015 May;29(5):1060-8. doi: 10.1038/leu.2014.335. PubMed PMID: 25434303.

Röllig C, Schäfer-Eckardt K, Hänel M, Kramer M, Schaich M, Thiede C, Oelschlägel U, Mohr B, Wagner T, Einsele H, Krause SW, Bodenstein H, Martin S, Stuhlmann R, Ho AD, Bornhäuser M, Ehninger G, Schuler U, Platzbecker U. Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trial. Ann Hematol. 2015 Apr;94(4):557-63. doi: 10.1007/s00277-014-2242-6. PubMed PMID: 25366167.

2014

Röllig C, Bornhäuser M, Kramer M, Thiede C, Ho AD, Krämer A, Schäfer-Eckart K, Wandt H, Hänel M, Einsele H, Aulitzky WE, Schmitz N, Berdel WE, Stelljes M, Müller-Tidow C, Krug U, Platzbecker U, Wermke M, Baldus CD, Krause SW, Stölzel F, von Bonin M, Schaich M, Serve H, Schetelig J, Ehninger G. Allogeneic Stem-Cell Transplantation in Patients With NPM1-Mutated Acute Myeloid Leukemia: Results From a Prospective Donor Versus No-Donor Analysis of Patients After Upfront HLA Typing Within the SAL-AML 2003 Trial. J Clin Oncol. 2014 Dec 29. pii: JCO.2013.54.4973. [Epub ahead of print] PubMed PMID: 25547501.

Schetelig J, Schaich M, Schäfer-Eckart K, Hänel M, Aulitzky WE, Einsele H, Schmitz N, Rösler W, Stelljes M, Baldus CD, Ho AD, Neubauer A, Serve H, Mayer J, Berdel WE, Mohr B, Oelschlägel U, Parmentier S, Röllig C, Kramer M, Platzbecker U, Illmer T, Thiede C, Bornhäuser M, Ehninger G. Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial. Leukemia. 2014 Dec 1. doi: 10.1038/leu.2014.335. [Epub ahead of print] PubMed PMID: 25434303.

Röllig C, Schäfer-Eckardt K, Hänel M, Kramer M, Schaich M, Thiede C, Oelschlägel U, Mohr B, Wagner T, Einsele H, Krause SW, Bodenstein H, Martin S, Stuhlmann R, Ho AD, Bornhäuser M, Ehninger G, Schuler U, Platzbecker U. Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trial. Ann Hematol. 2014 Nov 5. [Epub ahead of print] PubMed PMID: 25366167.

Herold T, Metzeler KH, Vosberg S, Hartmann L, Röllig C, Stölzel F, Schneider S, Hubmann M, Zellmeier E, Ksienzyk B, Jurinovic V, Pasalic Z, Kakadia PM, Dufour A, Graf A, Krebs S, Blum H, Sauerland MC, Büchner T, Berdel WE, Woermann BJ, Bornhäuser M, Ehninger G, Mansmann U, Hiddemann W, Bohlander SK, Spiekermann K, Greif PA. Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis. Blood. 2014 Aug 21;124(8):1304-11. doi: 10.1182/blood-2013-12-540716. Epub 2014 Jun 12. PubMed PMID: 24923295.

Middeke JM, Fang M, Cornelissen JJ, Mohr B, Appelbaum FR, Stadler M, Sanz J, Baurmann H, Bug G, Schäfer-Eckart K, Hegenbart U, Bochtler T, Röllig C, Stölzel F, Walter RB, Ehninger G, Bornhäuser M, Löwenberg B, Schetelig J. Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Blood. 2014 May 8;123(19):2960-7. doi: 10.1182/blood-2013-12-544957. Epub 2014 Mar 20. PubMed PMID: 24652988.

2013

Shayegi N, Kramer M, Bornhäuser M, Schaich M, Schetelig J, Platzbecker U, Röllig C, Heiderich C, Landt O, Ehninger G, Thiede C. The level of redidual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood. 2013 May 8. [Epub ahead of print] PubMed PMID: 23656730

Stölzel F, Platzbecker U, Mohr B, Röllig C, Middeke JM, Thiede C, Füssel M, Hänel M, Schaich M, Ehninger G, Schetelig J, Bornhäuser M. Early intervention with allogeneic hematopoietic cell transplantation during chemotherapy-induced aplasia in patients with high-risk acute myeloid leukemia. Leukemia. 2013 May 7. doi: 10.1038/leu.2013.142. [Epub ahead of print] No abstract available. PubMed PMID: 23648670

Mohr B, Schetelig J, Schäfer-Eckart K, Schmitz N, Hänel M, Rösler W, Frickhofen N, Link H, Neubauer A, Schuler U, Platzbecker U, Middeke JM, Ehninger G, Bornhäuser M, Schaich M, Stölzel F; Study Alliance Leukaemia (SAL). Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemia. Br J Haematol. 2013 Apr; 161(2):237-44. doi: 10.1111/bjh.12253. Epub 2013 Epub 2013 Feb 21. PMID: 23432431

Schaich M, Parmentier S, Kramer M, Illmer T, Stölzel F, Röllig C, Thiede C, Hänel M, Schäfer-Eckart K, Aulitzky W, Einsele H, Ho AD, Serve H, Berdel WE, Mayer J, Schmitz N, Krause SW, Neubauer A, Baldus CD, Schetelig J, Bornhäuser M, Ehninger G. High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial. J Clin Oncol. 2013 Apr 29. [Epub ahead of print]. PubMed PMID: 23630210

Mikesch JH, Kuhlmann M, Demant A, Krug U, Thoennissen GB, Schmidt E, Kessler T, Schliemann C, Pohlen M, Mohr M, Evers G, Köhler G, Wessling J, Mesters R, Müller-Tidow C, Berdel WE, Thoennissen NH. DexeBEAM versus ICE salvage regimen prior to autologous tranplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient chorts of one center. Ann Hematol. 2013 Mar 27. [Epub ahead of print]. PubMed PMID: 23532626

2012

Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M, Mahlknecht U, Ho A, Schaich M, Kramer M, Kaufmann M, Leimer L, Schwerdtfeger R, Conradi R, Dölken G, Klenner A, Hänel M, Herbst R, Junghanss C, Ehninger G; Study Alliance Lekemia. Therapeutic platelet transfusion versus routune prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet. 2012 Oct 13;380(9850):1309-16. doi: 10.1016/S0140-6736(12)60689-8. Epub 2012 Aug 8. PubMed PMID: 22877506

Büchner T, Schlenk RF, Schaich M, Döhner K, Krahl R, Krauter J, Heil G, Krug U, Sauerland MC, Heinecke A, Späth D, Kramer M, Scholl S, Berdel WE, Hiddemann W, Hoelzer D, Hehlmann R, Hasford J, Hoffmann VS, Döhner H, Ehninger G, Ganser A, Niederwieser DW, Pfirrmann M. Acute Myeloid Leukemia (AML): different treatment strategies versus a commin standard arm--combined prospective analysis by the German AML Intergroup. J Clin Oncol. 2012 Oct 10;30(29:3604-10. doi: 10.1200/JCO.2012.42.2907. Wpub 2012 Sep 10. PubMed PMID: 22965967

Bornhäuser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, Baurmann H, Schäfer-Eckart K, Holler E, Kröger N, Schmid C, Einsele H, Kiehl MG, Hiddemann W, Schwerdtfeger R, Buchholz S, Dreger P, Neubauer A, Berdel WE, Ehninger G, Beelen DW, Schetelig J, Stelljes M. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012 Sep 6.

Reddy PN, Sargin B, Choudhary C, Stein S, Grez M, Müller-Tidow C, Berdel WE, Serve H, Brandts CH, Study Alliance Leukemia (SAL). SOCS1 cooperates with FLT3-ITD in the development of myeloprolifertive disease by promoting the escape from external cytokine control. Blood. 2012 Aug 23;120(8):1691-702. Epub 2012 Apr 19. PubMed PMID: 22517899.

Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M, Mahlknecht U, Ho A, Schaich M, Kramer M, Kaufmann M, Leimer L, Schwerdtfeger R, Conradi R, Dölken G, Klenner A, Hänel M, Herbst R, Junghanss C, Ehninger G; for the Study Alliance Leukemia. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet. 2012 Aug 6.

Middeke JM, Beelen D, Stadler M, Göhring G, Schlegelberger B, Baurmann H, Bug G, Bellos F, Mohr B, Buchholz S, Schwerdtfeger R, Martin H, Hegenbart U, Ehninger G, Bornhäuser M, Schetelig J. Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-. Blood. 2012 Jul 31.

Krug U, Koschmieder A, Schwammbach D, Gerss J, Tilow N, Steffen B, Bug G, Brandts CH, Schaich M, Röllig C, Thiede C, Noppeney R, Stelljes M, Büchner T, Koschmieder S, Dührsen U, Serve H, Ehninger G, Berdel WE, Müller-Tidow C. Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leikemia--a randomised SAL pilot study. PLoS One. 2012;7(12):e52695. doi: 10.1371/journal.pone.0052695. Epub 2012 Dec 31. PubMed PMID: 23300745.

Röllig C, Brandts C, Shaid S, Hentrich M, Krämer A, Junghanß C, Schleyer E, Müller-Tidow C, Berdel WE, Ritter B, Pflüger KH, Kramer M, Haibach M, Ehninger G, Serve H, Krause SW. Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. Leuk Lymphoma. 2012 Jun;53(6):1062-7.

Parmentier S, Schetelig J, Lorenz K, Kramer M, Ireland R, Schuler U, Ordemann R, Rall G, Schaich M, Bornhäuser M, Ehninger G, Kroschinsky F. Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors. Haematologica. 2012 May;97(5):723-30.

Brunnberg U, Mohr M, Noppeney R, Dürk HA, Sauerland MC, Müller-Tidow C, Krug U, Koschmieder S, Kessler T, Mesters RM, Schulz C, Kosch M, Büchner T, Ehninger G, Dührsen U, Serve H, Berdel WE. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients. Ann Oncol. 2012 Apr;23(4):990-6.

Agrawal-Singh S, Isken F, Agelopoulos K, Klein HU, Thoennissen NH, Koehler G, Hascher A, Bäumer N, Berdel WE, Thiede C, Ehninger G, Becker A, Schlenke P, Wang Y, McClelland M, Krug U, Koschmieder S, Büchner T, Yu DY, Singh SV, Hansen K, Serve H, Dugas M, Müller-Tidow C. Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. Blood. 2012 Mar 8;119(10):2346-57.

Pfirrmann M, Ehninger G, Thiede C, Bornhäuser M, Kramer M, Röllig C, Hasford J, Schaich M; Study Alliance Leukaemia (SAL). Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. Lancet Oncol. 2012 Feb;13(2):207-14.

2011

Röllig C, Bornhäuser M, Thiede C, Taube F, Kramer M, Mohr B, Aulitzky W, Bodenstein H, Tischler HJ, Stuhlmann R, Schuler U, Stölzel F, von Bonin M, Wandt H, Schäfer-Eckart K, Schaich M, Ehninger G. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol. 2011 Jul 10;29(20):2758-65. Epub 2011 May 31. PubMed PMID: 21632498

Schaich M, Röllig C, Soucek S, Kramer M, Thiede C, Mohr B, Oelschlaegel U, Schmitz N, Stuhlmann R, Wandt H, Schäfer-Eckart K, Aulitzky W, Kaufmann M, Bodenstein H, Tischler J, Ho A, Krämer A, Bornhäuser M, Schetelig J, Ehninger G. Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. J Clin Oncol. 2011 Jul 1;29(19):2696-702. Epub 2011 May 23. PubMed PMID: 21606413.

Tickenbrock L, Klein HU, Trento C, Hascher A, Göllner S, Bäumer N, Kuss R, Agrawal S, Bug G, Serve H, Thiede C, Ehninger G, Stadt UZ, McClelland M, Wang Y, Becker A, Koschmieder S, Berdel WE, Dugas M, Müller-Tidow C; Study Alliance Leukemia Group. Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival. Leuk Res. 2011 May;35(5):620-5.

Stölzel F, Pfirrmann M, Aulitzky WE, Kaufmann M, Bodenstein H, Bornhäuser M, Röllig C, Kramer M, Mohr B, Oelschlägel U, Schmitz N, Soucek S, Thiede C, Ehninger G, Schaich M; Study Alliance Leukemia. Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial. Leukemia. 2011 Mar;25(3):420-8.

2010

Röllig C, Thiede C, Gramatzki M, Aulitzky W, Bodenstein H, Bornhäuser M, Platzbecker U, Stuhlmann R, Schuler U, Soucek S, Kramer M, Mohr B, Oelschlaegel U, Stölzel F, von Bonin M, Wermke M, Wandt H, Ehninger G, Schaich M; Study Alliance Leukemia. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood. 2010 Aug 12;116 (6):971-8. Epub 2010 May 4. PubMed PMID: 20442365.

Müller-Tidow C, Klein HU, Hascher A, Isken F, Tickenbrock L, Thoennissen N, Agrawal-Singh S, Tschanter P, Disselhoff C, Wang Y, Becker A, Thiede C, Ehninger G, zur Stadt U, Koschmieder S, Seidl M, Serve H, Müller FU, Schmitz W, Schlenke P, McClelland M, Berdel WE, Dugas M, Serve H; Study Alliance Leukemia. Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia. Blood. 2010 Nov 4;116(18):3564-71. Epub 2010 May 24. PubMed PMID: 20498303; PubMed Central PMCID: PMC2981478.

Krug U, Röllig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, Thiede C, Kramer M, Braess J, Spiekermann K, Haferlach T, Haferlach C, Koschmieder S, Rohde C, Serve H, Wörmann B, Hiddemann W, Ehninger G, Berdel WE, Büchner T, Müller-Tidow C; German Acute Myeloid Leukemia Cooperative Group; Study Alliance Leukemia Investigators. Complete remission and early death after intensive Chemotherapy in patients aged 60 years or older with acute myeloid leukemia: a web-based application for prediction of outcomes. Lancet. 2010 Dec 11;376(9757):2000-8. Epub 2010 Dec 3. PubMed PMID: 21131036.

Tickenbrock L, Klein HU, Trento C, Hascher A, Göllner S, Bäumer N, Kuss R, Agrawal S, Bug G, Serve H, Thiede C, Ehninger G, Stadt UZ, McClelland M, Wang Y, Becker A, Koschmieder S, Berdel WE, Dugas M, Müller-Tidow C; for the SAL (Study Alliance Leukemia) Group. Increased HDAC1 deposition at hematopoietic promoters with patient survival. Leuk Res. 2011 May;35(5):620-625. Epub 2010 Dec 22. PubMed PMID: 21176959.

Stölzel F, Pfirrmann M, Aulitzky WE, Kaufmann M, Bodenstein H, Bornhäuser M, Röllig C, Kramer M, Mohr B, Oelschlägel U, Schmitz N, Soucek S, Thiede C, Ehninger G, Schaich M; Study Alliance Leukemia. Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial. Leukemia. 2011 Mar;25(3):420-8. Epub 2010 Dec 7. PubMed PMID: 21135859.

2009

Mahlknecht U, Dransfeld CL, Bulut N, Kramer M, Thiede C, Ehninger G, Schaich M. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival. Leukemia. 2009 Oct;23(10):1929-32. Epub 2009 May 21. PubMed PMID: 19458626.

Oelschlaegel U, Mohr B, Schaich M, Schäkel U, Kroschinsky F, Illmer T, Ehninger G, Thiede C. HLA-DRneg patients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia. Cytometry B Clin Cytom. 2009 Sep;76(5):321-7. PubMed PMID: 19291801.

Krauter J, Wagner K, Schäfer I, Marschalek R, Meyer C, Heil G, Schaich M, Ehninger G, Niederwieser D, Krahl R, Büchner T, Sauerland C, Schlegelberger B, Döhner K, Döhner H, Schlenk RF, Ganser A. Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2009 Jun 20;27(18):3000-6. Epub 2009 Apr 20. PubMed PMID: 19380453.

Strunk CJ, Platzbecker U, Thiede C, Schaich M, Illmer T, Kang Z, Leahy P, Li C, Xie X, Laughlin MJ, Lazarus HM, Gerson SL, Bunting KD, Ehninger G, Tse W. Elevated AF1q expression is a poor prognostic marker for adult acute myeloid leukemia patients with normal cytogenetics. Am J Hematol. 2009 May;84(5):308-9. PubMed PMID: 19396856.

Seifert H, Mohr B, Thiede C, Oelschlägel U, Schäkel U, Illmer T, Soucek S, Ehninger G, Schaich M; Study Alliance Leukemia (SAL). The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia. Leukemia. 2009 Apr;23(4):656-63. Epub 2009 Jan 8. PubMed PMID: 19151774.

Guo Y, Köck K, Ritter CA, Chen ZS, Grube M, Jedlitschky G, Illmer T, Ayres M, Beck JF, Siegmund W, Ehninger G, Gandhi V, Kroemer HK, Kruh GD, Schaich M. Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival. Clin Cancer Res. 2009 Mar 1;15(5):1762-9. Epub 2009 Feb 24. PubMed PMID: 19240178.

Seifert H, Mohr B, Thiede C, Oelschlägel U, Schäkel U, Illmer T, Soucek S, Ehninger G, Schaich M; Study Alliance Leukemia (SAL). The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia. Leukemia. 2009 Apr;23(4):656-63. Epub 2009 Jan 8. PubMed PMID: 19151774

Bandi SR, Brandts C, Rensinghoff M, Grundler R, Tickenbrock L, Köhler G, Duyster J, Berdel WE, Müller-Tidow C, Serve H, Sargin B; Study Alliance Leukemias. E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. Blood. 2009 Nov 5;114(19):4197-208.

2008

Fierro FA, Brenner S, Oelschlaegel U, Jacobi A, Knoth H, Ehninger G, Illmer T, Bornhäuser M. Combining SDF-1/CXCR4 antagonism and chemotherapy in relapsed acute myeloid leukemia. Leukemia. 2009 Feb;23(2):393-6. Epub 2008 Jul 10. PubMed PMID: 18615106.

Bornhäuser M, Illmer T, Oelschlaegel U, Schetelig J, Ordemann R, Schaich M, Hänel M, Schuler U, Thiede C, Kiani A, Platzbecker U, Ehninger G. Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia. Clin Cancer Res. 2008 Sep 1;14(17):5585-93. PubMed PMID: 18765552.

Haentzschel I, Freiberg-Richter J, Platzbecker U, Kiani A, Schetelig J, Illmer T, Ehninger G, Schleyer E, Bornhäuser M. Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Bone Marrow Transplant. 2008 Jul;42(2):113-20. Epub 2008 Mar 24. PubMed PMID: 18362900.

Messerer D, Engel J, Hasford J, Schaich M, Ehninger G, Sauerland C, Büchner T, Schumacher A, Krahl R, Niederwieser D, Krauter J, Ganser A, Creutzig U, Döhner H, Schlenk RF; German AML Intergroup. Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia. Haematologica. 2008 Jun;93(6):826-33. Epub 2008 May 10. PubMed PMID: 18469349.

Fierro FA, Taubenberger A, Puech PH, Ehninger G, Bornhauser M, Muller DJ, Illmer T. BCR/ABL expression of myeloid progenitors increases beta1-integrin mediated adhesion to stromal cells. J Mol Biol. 2008 Apr 4;377(4):1082-93. Epub 2008 Feb 5. PubMed PMID: 18313694.

2007

Wandt H, Schäkel U, Kroschinsky F, Prange-Krex G, Mohr B, Thiede C, Pascheberg U, Soucek S, Schaich M, Ehninger G. MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. Blood. 2008 Feb 15;111(4):1855-61. Epub 2007 Dec 4. PubMed PMID: 18056840.

Kroschinsky FP, Schäkel U, Fischer R, Mohr B, Oelschlaegel U, Repp R, Schaich M, Soucek S, Baretton G, Ehninger G, Thiede C; DSIL (Deutsche Studieninitiative Leukämie) Study Group. Cup-like acute myeloid leukemia: new disease or artificial phenomenon? Haematologica. 2008 Feb;93(2):283-6. Epub 2008 Jan 26. PubMed PMID: 18223289.

Dransfeld CL, Schaich M, Ho AD, Thiede C, Ehninger G, Mahlknecht U. Class I HDAC SNP analysis in healthy donors compared to AML patients. Leukemia. 2007 Jul;21(7):1587-90. Epub 2007 Apr 5. PubMed PMID: 17410193.

Schaich M, Schlenk RF, Al-Ali HK, Döhner H, Ganser A, Heil G, Illmer T, Krahl R, Krauter J, Sauerland C, Büchner T, Ehninger G. Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. Haematologica. 2007 Jun;92(6):763-70. PubMed PMID: 17550848.

Bornhäuser M, Illmer T, Schaich M, Soucek S, Ehninger G, Thiede C; AML SHG 96 study group. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood. 2007 Mar 1;109(5):2264-5; author reply 2265. PubMed PMID: 17312001.

Illmer T, Schaich M, Ehninger G, Thiede C; DSIL2003 AML study group. Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias. Haematologica. 2007 Jan;92(1):137-8. PubMed PMID: 17229652.

2006

Platzbecker U, Germing U, Schäkel U, Illmer T, Soucek S, Schaich M, Ehninger G, Thiede C. Association with the single-nucleotide polymorphism (Glu785Lys) of the granulocyte colony-stimulating factor receptor with myelodysplastic syndromes and acute myeloid leukemia with multlineage dysplasia. Leukemia. 2006 Dec;20(12):2188-9. Epub 2006 Oct 5. PubMed PMID: 17024119.

Thiede C, Creutzig E, Illmer T, Schaich M, Heise V, Ehninger G, Landt O. Rapid and sensitive typing of NPM1 mutations using LNA-mediated PCR clamping. Leukemia. 2006 Oct;20(10):1897-9. Epub 2006 Sep 7. PubMed PMID: 17041639.

Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006 May 15;107(10):4011-20. Epub 2006 Feb 2. PubMed PMID: 16455956.

Platzbecker U, Thiede C, Füssel M, Geissler G, Illmer T, Mohr B, Hänel M, Mahlberg R, Krümpelmann U, Weissinger F, Schaich M, Theuser C, Ehninger G, Bornhäuser M. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia. 2006 Apr;20(4):707-14. PubMed PMID: 16482208.

2005

Strodtbeck D, Bornhäuser M, Hänel M, Lerche L, Schaich M, Illmer T, Thiede C, Geissler G, Herbst R, Ehninger G, Platzbecker U. Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission. Bone Marrow Transplant. 2005 Dec;36(12):1083-8. PubMed PMID: 16247435.

Illmer T, Thiede C, Fredersdorf A, Stadler S, Neubauer A, Ehninger G, Schaich M. Activation of the RAS pathway is predictive for a chemosensitive phenotype of acute myelogenous leukemia blasts. Clin Cancer Res. 2005 May 1;11(9):3217-24. PubMed PMID: 15867216.

Schaich M, Soucek S, Thiede C, Ehninger G, Illmer T; SHG AML96 Study Group. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol. 2005 Feb;128(3):324-32. PubMed PMID: 15667534.

Bornhäuser M, Eger L, Oelschlaegel U, Auffermann-Gretzinger S, Kiani A, Schetelig J, Illmer T, Schaich M, Corbeil D, Thiede C, Ehninger G. Rapid reconstitution of dendritic cells after allogeneic transplantation of CD133+ selected hematopoietic stem cells. Leukemia. 2005 Jan;19(1):161-5. PubMed PMID: 15510205.


2004

Schaich M, Koch R, Soucek S, Repp R, Ehninger G, Illmer T. A sensitive model for prediction of relapse in adult acute myeloid leukaemia with t(8;21) using white blood cell count, CD56 and MDR1 gene expression at diagnosis. Br J Haematol. 2004 May;125(4):477-9. PubMed PMID: 15142118.

2003

Steudel C, Wermke M, Schaich M, Schäkel U, Illmer T, Ehninger G, Thiede C. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. Genes Chromosomes Cancer. 2003 Jul;37(3):237-51. PubMed PMID: 12759922.

2002

Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, Freund D, Schäkel U, Ehninger G, Schaich M. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 2002 Sep 1;62(17):4955-62. PubMed PMID: 12208746.

Schaich M, Illmer T, Aulitzky W, Bodenstein H, Clemens M, Neubauer A, Repp R, Schäkel U, Soucek S, Wandt H, Ehninger G; SHG AML96 Study Group. Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years. Haematologica. 2002 Aug;87(8):808-15. PubMed PMID: 12161356.

Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, Wermke M, Bornhäuser M, Ritter M, Neubauer A, Ehninger G, Illmer T. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002 Jun 15;99(12):4326-35. PubMed PMID: 12036858.

Schaich M, Harbich-Brutscher E, Pascheberg U, Mohr B, Soucek S, Ehninger G, Illmer T. Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication in treatment outcome. Haematologica. 2002 May;87(5):455-64. PubMed PMID: 12010657.

2001

Schaich M, Illmer T, Seitz G, Mohr B, Schäkel U, Beck JF, Ehninger G. The prognostic value of Bcl-XL gene expression for remission induction is influenced by cytogenetics in adult acute myeloid leukemia. Haematologica. 2001 May;86(5):470-7. PubMed PMID: 11410409.

Platzbecker U, Thiede C, Freiberg-Richter J, Röllig C, Helwig A, Schäkel U, Mohr B, Schaich M, Ehninger G, Bornhäuser M. Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia. Bone Marrow Transplant. 2001 Mar;27(5):543-6. PubMed PMID: 11313690.

Schaich M, Ritter M, Illmer T, Lisske P, Thiede C, Schäkel U, Mohr B, Ehninger G, Neubauer A. Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia. Br J Haematol. 2001 Feb;112(2):300-7. PubMed PMID: 11167822.

2000

Mohr B, Bornhäuser M, Thiede C, Schäkel U, Schaich M, Illmer T, Pascheberg U, Ehninger G. Comparison of spectral karyotyping and conventional cytogenetics in 39 patients with acute myeloid leukemia and myelodysplastic syndrome. Leukemia. 2000 Jun;14(6):1031-8. PubMed PMID: 10865969.

1999

Illmer T, Schaich M, Oelschlägel U, Nowak R, Renner U, Ziegs B, Subat S, Neubauer A, Ehninger G. A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples. Leuk Res. 1999 Jul;23(7):653-63. PubMed PMID: 10400187.

16.10.2018
Hotline

Fragen zu AML-Therapie und AML-Studien:

Tel:+49(0)351 458 4969

E-Mail senden

Fragen zu MPN-Therapie und MPN-Studien:

Tel:+49(0)241 80 37029

E-Mail senden

Fragen zu APL-Therapie und APL-Studien:

Tel:+49(0)351 458 3192

E-Mail senden

Registrierung

Melden Sie Ihr Zentrum
schnell und einfach
fürs
AML-Register,
MPN-Register und
APL-Register an.

SAL Studienzentren